Projects & Grants
| Use of Pentraxin 3 in the differential diagnosis of aspergillus syndrome | |
|---|---|
| Project Id | SGS01-2021 |
| Main solver | Mgr. Radim Dobiáš, Ph.D. |
| Period | 1/2021 - 12/2021 |
| Provider | Specifický VŠ výzkum |
| State | finished |
| Anotation | The most clinically important member of the genus Aspergillus is Aspergillus fumigatus. Due to the small size of the spores, it penetrates deep into the human respiratory system and can cause various types of clinical problems under certain conditions. From hypersensitivity pneumonia through allergic bronchopulmonary aspergillosis to the most severe form, invasive aspergillosis. The wide potential of this opportunistic pathogen applies to both outpatients and critically ill patients, where their primary involvement of the respiratory system or immune system allows this ubiquitous fungal microorganism to interact with the human body. This can occur due to primary hypersensitivity, immunodeficiency due to oncological diseases and their therapy, due to severe respiratory infections (H1N1, COVID19, bacterial infections), long-term antibiotic treatment and massive corticotherapy. A variety of biomarkers are used in the diagnosis of the clinical units listed above. Due to the need to diagnose or differentiate these clinical units earlier, methods for detecting specific early human inflammatory biomarkers, including Pentraxin 3 (PTX3), have also recently been added to combination with conventional techniques. The aim of this work is to map the concentrations of PTX3 in serum and bronchoalveolar lavage and to evaluate together with the concentration of specific IgG and IgE against A. fumigatus in the serum of patients with suspected above-mentioned diagnoses. Detection of PTX3, IgG and IgE concentrations will be performed observationally and retrospectively from 400 diagnostically collected patient serum samples for the period 2015 - 2020. By analyzing the data obtained in this study, we obtain results that should serve in the future to better distinguish between hypersensitivity pneumonia, allergic bronchopulmonary aspergillosis and invasive aspergillosis. The obtained data will follow up the current successfully published research of the principal investigator. |
